Table 2.
Summary of existing evidence of tyrosine kinase involvement in immunopathogenesis of immune-mediated GN
| Tyrosine kinase | Disease | In vitro study | In vivo study | Human renal biopsy study | Justifiable for further clinical study |
|---|---|---|---|---|---|
| Spleen tyrosine kinase | Anti-GBM disease | √ | √ | √ | √ |
| AAGN | √ | √ | √ | √ | |
| LN | √ | √ | √ | √ | |
| IgAN | √ | No representative animal model | √ | √ | |
| Bruton's tyrosine kinase | Anti-GBM disease | √ | √ | No data | Insufficient evidence |
| AAGN | No data | No data | No data | Insufficient evidence | |
| LN | √ | √ | No data | Insufficient evidence | |
| IgAN | No data | No representative animal model | No data | Insufficient evidence | |
| Platelet-derived growth factor receptor | Anti-GBM disease | √ | Conflicting data | No data | Insufficient evidence |
| AAGN | No data | No data | No data | Insufficient evidence | |
| LN | √ | √ | No data | Insufficient evidence | |
| IgAN | √ | √ (in anti-Thy 1.1 model) | √ | √ | |
| Epidermal growth factor receptor | Anti-GBM disease | √ | √ | √ | √ |
| AAGN | No data | No data | No data | Insufficient evidence | |
| LN | √ | √ | √ | √ | |
| IgAN | √ | √ (in anti-Thy 1.1 model) | No data | Insufficient evidence | |
| Discoidin domain receptor 1 | Anti-GBM disease | √ | √ | √ | √ |
| AAGN | No data | No data | No data | Insufficient evidence | |
| LN | √ | √ | √ | √ | |
| IgAN | No data | No representative animal model | No data | Insufficient evidence | |
| Janus kinase | LN | √ | √ | No data | Insufficient evidence |
| Vascular endothelial growth factor | IgAN | √ | No representative animal model | √ | √ |